Table 1.
Summary of ROS1 fusion prevalence and statistical analysis of subgroups classified by clinicopathological characteristics
| Features | All NSCLC patients | |||
|---|---|---|---|---|
| ROS1 positive | ROS1 negative | Total | P | |
| Age (years, Mean ± SD) | 56.09 ± 11.38 | 61.23 ± 10.55 | 61.11 ± 10.60 | <0.001† |
| Gender (n, %) | <0.001‡ | |||
| Female | 92 (3.71%) | 2390 (96.29%) | 2482 | |
| Male | 65 (1.81%) | 3519 (98.19%) | 3584 | |
| Smoking history (n, %) | <0.001‡ | |||
| Non‐smoker | 111 (3.33%) | 3218 (96.67%) | 3329 | |
| Smoker | 23 (1.21%) | 1880 (98.79%) | 1903 | |
| NA | 23 (2.76%) | 811 (97.24%) | 834 | |
| Pathological types (n, %) | 0.01742‡ | |||
| Adenocarcinoma | 136 (2.77%) | 4776 (97.23%) | 4912 | |
| Squamous carcinoma | 4 (0.93%) | 426 (99.07%) | 430 | |
| Others | 17 (2.35%) | 707 (97.65%) | 724 | |
| Pathological stage (n, %) | 0.6826§ | |||
| 0 | 0.00% | 16 (100.00%) | 16 | |
| I | 13 (2.19%) | 580 (97.81%) | 593 | |
| II | 6 (2.18%) | 269 (97.82%) | 275 | |
| III | 34 (3.27%) | 1006 (96.73%) | 1040 | |
| IV | 75 (2.59%) | 2824 (97.41%) | 2899 | |
| NA | 29 (2.33%) | 1214 (97.67%) | 1243 | |
| T stage (n, %) | 0.1567§ | |||
| T1 | 12 (3.20%) | 363 (96.80%) | 375 | |
| T2 | 17 (2.66%) | 623 (97.34%) | 640 | |
| T3 | 3 (1.05%) | 283 (98.95%) | 286 | |
| T4 | 23 (2.04%) | 1102 (97.96%) | 1125 | |
| NA | 102 (2.80%) | 3538 (97.20%) | 3640 | |
| N stage (n, %) | 0.0171§ | |||
| N0 | 6 (1.31%) | 451 (98.69%) | 457 | |
| N1 | 4 (1.40%) | 282 (98.60%) | 286 | |
| N2 | 18 (2.07%) | 853 (97.93%) | 871 | |
| N3 | 26 (3.23%) | 779 (96.77%) | 805 | |
| NA | 103 (2.82%) | 3544 (97.18%) | 3647 | |
| M stage (n, %) | 1‡ | |||
| M0 | 20 (2.29%) | 854 (97.71%) | 874 | |
| M1 | 34 (2.29%) | 1448 (97.71%) | 1482 | |
| NA | 103 (2.78%) | 3607 (97.22%) | 3710 | |
†
Two‐tailed Student's t‐test.
‡
Fisher's exact test.
§
Chi‐square test for trend.
NA, not available; NSCLC, non‐small cell lung cancer; SD, standard deviation.